{"id":"W4283020357","doi":"10.3390/curroncol29060348","title":"A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Fluidigm (Canada); McGill University; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; Jewish General Hospital; Sunnybrook Health Science Centre; Sinai Health System; University of Manitoba; CancerCare Manitoba; Occupational Cancer Research Centre; Health Sciences Centre; University Health Network; University of Toronto; University of British Columbia","funders":"AstraZeneca Canada","keywords":"Olaparib; Medicine; PARP inhibitor; Oncology; Maintenance therapy; Ovarian cancer; Internal medicine; Serous fluid; Carboplatin; Chemotherapy; Gynecology; Front line; Poly ADP ribose polymerase; Intensive care medicine; Cisplatin; Cancer; Polymerase; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02044031,0.0009623455,0.001581451,0.003453899,0.003899817,0.002823304,0.006835852,0.006247372,0.003293868],"category_scores_gemma":[0.02585085,0.0006443874,0.002977148,0.004288976,0.002831324,0.001555705,0.002579933,0.008032394,0.001923113],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0301227,"about_ca_system_score_gemma":0.149814,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.5343627,"about_ca_topic_score_gemma":0.7111721,"domain_scores_codex":[0.9858686,0.002946114,0.002525949,0.0006186947,0.006632671,0.001408014],"domain_scores_gemma":[0.9488933,0.004304648,0.003016524,0.00057061,0.03684489,0.006369981],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001052606,0.0000609657,0.002077336,0.002274579,0.00008294728,0.0003394539,0.0003628297,0.0007155813,0.0008025159,0.004646515,0.8417514,0.1467807],"study_design_scores_gemma":[0.00006891722,0.00004838506,0.004076156,0.004368742,0.0001217222,0.0004946891,0.0003877483,0.0002599961,0.000424677,0.001930238,0.987755,0.00006370482],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.003276865,0.2181001,0.009734931,0.6741953,0.03038237,0.001293282,0.004198267,0.0003410715,0.05847785],"genre_scores_gemma":[0.0753942,0.3966725,0.110043,0.3274258,0.01252041,0.001938008,0.01773905,0.0003869682,0.05788001],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.9698773,"threshold_uncertainty_score":0.936759,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07324022133867346,"score_gpt":0.3717722777892413,"score_spread":0.2985320564505679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}